跳至主要内容
临床试验/NCT02890875
NCT02890875终止不适用

Efficacy and Safety of Ethanol Lock Therapy for the Prevention of Central Line-associated Bloodstream Infections

Stanford University2 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2016年8月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
入组人数
3
试验地点
2
主要终点
Central line-associated bloodstream infection

研究概览

简要总结

Patients on long-term parenteral nutrition (PN) are at high risk for central line-associated bloodstream infections (CLABSI). This study evaluates the efficacy and safety of ethanol lock therapy for CLABSI prophylaxis in adult patients on PN.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients (ages 18-80) on PN with silicone-based central venous catheters

排除标准

  • Weight ≤ 50 kg
  • Allergy/hypersensitivity/intolerance to ethanol or heparin
  • Pregnancy or breastfeeding
  • Patient taking metronidazole, disulfiram, or isoniazid
  • History of alcohol abuse
  • History of heparin-induced thrombocytopenia (HIT) or have an active hypocoagulable state

研究组 & 干预措施

Ethanol lock

Active Comparator

70% ethanol

干预措施: Ethanol lock (Other)

Heparin lock

Active Comparator

Heparinized saline (100 U/mL)

干预措施: Heparin lock (Other)

结局指标

主要结局

Central line-associated bloodstream infection

时间窗: 12 months

次要结局

  • Catheter-related complication(12 months)
  • New self-reported symptoms(12 months)
  • Hospitalization(12 months)
  • SIRS/sepsis(12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Berkeley Limketkai

Clinical Assistant Professor

Stanford University

研究点 (2)

Loading locations...

相似试验